Independent Financial Group’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Independent Financial Group’s Portfolio TCRR Stock Details TCRR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-12,075	Closed	-$18.1K	–	935
2023 Q1	$18.1K	Hold	12,075	–	–	﹤0.01%	832
2022 Q4	$12.1K	Hold	12,075	–	–	﹤0.01%	777
2022 Q3	$21.7K	Hold	12,075	–	–	﹤0.01%	739
2022 Q2	$35K	Buy	12,075 +75	+0.6%	+$185	﹤0.01%	704
2022 Q1	$33.1K	Sell	12,000 -200	-2%	-$629	﹤0.01%	774
2021 Q4	$56.9K	Buy	+12,200	New	+$76.3K	﹤0.01%	767

Independent Financial Group's TCRR Position: Q2 2023 in Review

Independent Financial Group sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 12,075 shares — an estimated $18.1K sold.

Independent Financial Group first reported a position in TCRR in Q4 2021 and held it in 6 quarters. The position peaked at $56.9K in Q4 2021. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.

Independent Financial Group reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Independent Financial Group sold 12,075 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $18.1K.
Independent Financial Group first reported a position in TCR2 Therapeutics Inc. Common Stock in Q4 2021 and held it in 6 quarters.
Independent Financial Group's TCR2 Therapeutics Inc. Common Stock position peaked at $56.9K in Q4 2021.
0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.

Based on Independent Financial Group's 13F filing for Q2 2023, filed 12 Jun 2026.